Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved

Shanghai, China, June 10, 2020 – Boehringer Ingelheim is proud to announce that its China-developed Classical Swine Fever Vaccine, Live  (C-strain, PK/WRL  Cell Line Origin) (English trade name: Ingelvac^® CSF MLV) has recently obtained a “New Veterinary Drug Registration Certificate” from the Ministry of Agriculture and Rural Affairs of China. It is the first Classical Swine Fever live vaccine jointly developed by a multinational company and Chinese research institutes. It marks another milestone for Boehringer Ingelheim’s “in China, for China”, as the company is committed to providing innovative and high-quality swine vaccines for the Chinese swine industry, as well as holistic swine disease solutions to pig farms.

Classical Swine Fever (CSF) is a highly contagious and lethal infectious disease in pigs, caused by Classical Swine Fever Virus (CSFV). As the disease has caused huge economic losses to the pig farming industry, it is classified as Class A Animal Disease in China. Even though massive vaccination with CSF live vaccine in China now effectively controls the outbreak of CSF, endemic and sporadic spread still exists.

Most Classical Swine Fever live vaccines currently available on the market can only be stored at -15℃ for 18 months. Cold-chain transportation, storage and dilution all need a strict temperature control. The newly approved Ingelvac® CSF MLV uses state-of-the-art microcarrier-based suspension culture and freeze-drying technologies to ensure high-titer virus, stable vaccine production process, and controllable quality. It can be stored at 2-8℃ for 24 months. This high-quality product will provide China’s pig farming industry with breakthrough immunization programs and supporting disease solutions. It will contribute to the efforts and challenge of eradicating the Classical Swine Fever in China.

Ingelvac^® CSF MLV will be produced by Boehringer Ingelheim’s Taizhou plant, Jiangsu province, and it is expected to be commercialized in early 2021. It will become Boehringer Ingelheim’s first swine vaccine product, developed, manufactured and distributed in China. The Taizhou plant already manufactures Ingelvac^® PRRS MLV (live vaccine for porcine reproductive and respiratory syndrome).

Boehringer Ingelheim Animal Health

The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 10,000 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.

Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society- threatening diseases.

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4 billion euros in 2019 and presence in more than 150 countries.

For more information visit: www.boehringer-ingelheim.com/animal-health/overview.

In China, Boehringer Ingelheim Animal Health provides a broad portfolio including vaccines and pharmaceuticals for livestock and companion animals. It is currently the China market leader in swine, companion animals, and poultry products. The company’s China footprint covers the whole value chain from R&D, manufacturing to sales and technical services. Boehringer Ingelheim has established a leading veterinary R&D center and an Animal Health Management Center in Shanghai. Its manufacturing site in Nanchang mainly produces avian vaccines against diseases affecting poultry broilers and layers, as well as provides related vaccination technical services. In Taizhou, Jiangsu Province, the company’s world-class animal vaccine production site manufactures high-quality swine vaccines for China market.

Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.